Effects of metformin and ethinyl estradiol–cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome | Zendy

K Rautio | Zendy; Juha S. Tapanainen | Zendy; Aimo Ruokonen | Zendy; Laure MorinPapunen | Zendy

Open Access

Effects of metformin and ethinyl estradiol–cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

Author(s) -

K Rautio,

Juha S. Tapanainen,

Aimo Ruokonen,

Laure MorinPapunen

Publication year - 2005

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.1.01840

Subject(s) - polycystic ovary , medicine , endocrinology , metformin , cyproterone acetate , insulin resistance , dyslipidemia , triglyceride , population , metabolic syndrome , cyproterone , cholesterol , insulin , obesity , hormone , androgen , environmental health

Women with polycystic ovary syndrome (PCOS) exhibit risk factors for cardiovascular diseases such as abdominal obesity, insulin resistance and dyslipidemia. Insulin sensitizers, especially metformin, have been shown to improve these metabolic disturbances, but there are only a few studies on their effects on serum lipids in polycystic ovary syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research